>Estratest
Date Filed: August 7, 2003
Court: Superior Court
Location: California
Ticker Symbol: SVYSY

Hagens Berman has filed a lawsuit on behalf of several consumer groups against Solvay Pharmaceuticals claiming that the drug maker has engaged in false and illegal marketing of Estratest, a hormone replacement therapy drug the company has been marketing without FDA approval.

The suit alleges Solvay Pharmaceuticals marketing materials falsely stated that the hormone replacement therapy drug Estratest worked to treat hot flashes, something the FDA recently began questioning, and implied the drug was approved by the FDA.

Although Solvay applied for approval in 1981, the FDA never approved Estratest for its marketed use.

Several California-based consumer groups support the suit, including Congress of California Seniors and the California Public Interest Research Group (CALPIRG), along with Boston-based advocacy group Prescription Access Litigation project (PAL).
RECENT DEVELOPMENTS:

June 26, 2008 - Today the court issued a notice of class pendency for class members. The court ruled the case against Solvay Pharmaceuticals will move forward and plaintiffs have the option to do nothing, join the litigation or exclude themselves.

For additional information on your rights as a class member or your role in litigation, please review the notice of pendency. If you have additional questions on the case or your role please contact HBSS at info@hbsslaw.com.